F&V Capital Management’s Novavax NVAX Stock Holding History

F&V Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-750	Closed	-$17K	–	62
2017 Q3	$17K	Hold	750	–	–	0.01%	62
2017 Q2	$17K	Hold	750	–	–	0.01%	65
2017 Q1	$19K	Buy	750 +250	+50%	+$6.88K	0.01%	62
2016 Q4	$13K	Hold	500	–	–	0.01%	62
2016 Q3	$21K	Hold	500	–	–	0.01%	55
2016 Q2	$73K	Buy	+500	New	+$57.3K	0.05%	55

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

F&V Capital Management's NVAX Position: Q4 2017 in Review

F&V Capital Management sold out of Novavax (NVAX) in Q4 2017, closing a stake of 750 shares — an estimated $17K sold.

F&V Capital Management first reported a position in NVAX in Q2 2016 and held it in 6 quarters. The position peaked at $73K in Q2 2016. 134 funds tracked by Wall St. Rank hold NVAX as of Q4 2017.

F&V Capital Management reported no remaining Novavax position as of Q4 2017 after selling out during the quarter.
F&V Capital Management sold 750 Novavax shares in Q4 2017, an estimated $17K.
F&V Capital Management first reported a position in Novavax in Q2 2016 and held it in 6 quarters.
F&V Capital Management's Novavax position peaked at $73K in Q2 2016.
134 funds tracked by Wall St. Rank held Novavax as of Q4 2017.

Based on F&V Capital Management's 13F filing for Q4 2017, filed 10 Jan 2018.